REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.
Back to Research Library
GLP-1 receptor agoniststirzepatideexenatideliraglutidedulaglutidesemaglutide

Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.

May 16, 2026
Share

Source Paper

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun et al.Drug design, development and therapy2025
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

GLP-1 Receptor Agonists: Advancements in Pharmacokinetics and Drug Interactions

Published: May 16, 2026 | Source: Drug design, development and therapy (2025) | Category: GLP-1 receptor agonists, tirzepatide, exenatide, liraglutide, dulaglutide, semaglutide

Overview

A recent comprehensive review published in Drug Design, Development and Therapy provides critical insights into the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists (GLP-1 RAs) and a dual GLP-1/GIP receptor agonist. This study highlights how structural modifications to these peptides extend their half-life but may also increase the risk of adverse events, impacting clinical use in treating type 2 diabetes and obesity.

Study Background

GLP-1 RAs were initially developed to treat type 2 diabetes by mimicking the effects of natural GLP-1. However, native human GLP-1 has a very short half-life (approximately 2 minutes), necessitating structural modifications such as amino acid sequence changes, fatty acid conjugation, and fusion with albumin or Fc regions to enhance their therapeutic utility. The introduction of tirzepatide, which targets both GLP-1 and GIP receptors, further expanded the potential for these peptides in managing obesity.

What the Research Found

The review examines four approved GLP-1 RAs—exenatide, liraglutide, dulaglutide, and semaglutide—and tirzepatide. Key findings include:

  • Pharmacokinetics: Structural modifications have led to minimal metabolism and renal excretion for these peptides, resulting in prolonged half-lives compared to native GLP-1.
  • Drug-Drug Interactions (DDIs): Clinically significant DDIs mediated by drug-metabolizing enzymes or transporters are rare. However, mechanism-of-action-mediated DDIs involving delayed gastric emptying have been noted but generally considered clinically insignificant.
  • Specific Drug Interactions: Significant changes in exposure were observed for oral contraceptives and levothyroxine with the use of tirzepatide and semaglutide, respectively.

What This Means for Peptide Users

Clinicians need to be aware that while structural modifications have greatly improved the efficacy and convenience of GLP-1 RAs by extending their half-lives, they may also introduce new risks. For instance, patients taking oral contraceptives or levothyroxine should be closely monitored when using tirzepatide or semaglutide due to potential changes in drug exposure.

Limitations and Caveats

The review highlights several limitations:

  • Lack of Clinical Data: There is a dearth of clinical data on DDIs mediated by drug-metabolizing enzymes and transporters.
  • Volume of Distribution and Clearance Alterations: Further research is needed to understand how other mechanisms of action, such as changes in fat mass or cytochrome P450 activity, affect the pharmacokinetics of these peptides.

How This Compares to Previous Research

Previous studies have focused on individual GLP-1 RAs but lacked a comprehensive review that includes both pharmacokinetic profiles and DDIs. This study provides a consolidated view, making it easier for clinicians to understand the broader implications of using these therapies.

Our Analysis

PeptideVault's analysis suggests that while this review offers valuable insights into the current state of GLP-1 RAs and tirzepatide, there is still room for more detailed clinical studies on DDIs. The findings underscore the importance of personalized medicine approaches when prescribing these agents to ensure optimal safety and efficacy.

Key Takeaways

  • Structural Modifications: Enhance therapeutic utility but may increase adverse event risk.
  • DDI Monitoring: Clinicians should closely monitor patients using oral contraceptives or levothyroxine with tirzepatide or semaglutide.
  • Further Research Needed: Detailed clinical studies on DDIs and the impact of other mechanisms of action are essential.

Original Source

Citation: Min Jee Sun, Jo Seong Jun, Lee Sangyoung et al. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.. Drug design, development and therapy. DOI: 10.2147/DDDT.S506957

Access: https://pubmed.ncbi.nlm.nih.gov/40330819/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the Peptide Contacts research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

Related Research

Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.

tirzepatideGIP receptor agonistGLP-1 receptor agonist

Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.

semaglutideGLP-1 receptor agonist

Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.

liraglutideatrial natriuretic peptiderelaxin mimetics

Comments

Sign in to join the discussion

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.